 |
인쇄하기
취소
|
Hanhwa veers into biosimilar market
Hanhwa Chemical, a unit of conglomerate Hanhwa, is entering the global bio-similar market together with Dream Pharma, a local biotech firm.
Hanwha is set to conduct Phase I trial of ‘HD203’ (etanercept) under the approval of Korea Food and Drug Administration last month
Etanercept (Enbrel) is a drug that treats autoimmune diseases by interfering with the TNF receptor (a part of the immune...
Hanwha is set to conduct Phase I trial of ‘HD203’ (etanercept) under the approval of Korea Food and Drug Administration last month
Etanercept (Enbrel) is a drug that treats autoimmune diseases by interfering with the TNF receptor (a part of the immune...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.